Curated News
By: NewsRamp Editorial Staff
April 24, 2024
AGC Biologics Completes Production of Cancer-Specific Antibody Fragments with VAR2 Pharmaceuticals
Discuss on Reddit
Discuss on SubstackTLDR
- AGC Biologics completes production of cancer-specific antibody candidates for VAR2 Pharmaceuticals, offering a competitive edge in cancer treatment.
- AGC Biologics' work included method implementation, pilot-scale evaluations, and preparation for large-scale manufacturing of the antibody candidates.
- The collaboration between AGC Biologics and VAR2 Pharmaceuticals paves the way for first-in-human nuclear imaging microdosing study, potentially improving cancer treatment.
- VAR2 Pharmaceuticals' proprietary antibody fragments - Vartumabs - bind with high affinity to onco-fetal Chondroitin Sulfate, opening new possibilities in cancer therapy.
Impact - Why it Matters
The completion of this production project signifies a significant step in the development of potential cancer therapies. The collaboration between AGC Biologics and VAR2 Pharmaceuticals demonstrates the commitment to advancing innovative and effective cancer treatments, particularly for hard-to-treat, recurrent, and metastatic cancers. The successful outcome of this project paves the way for further efficacy trials and potential breakthroughs in cancer treatment.
Summary
AGC Biologics has successfully completed the production of cancer-specific therapeutic antibody fragments in collaboration with VAR2 Pharmaceuticals. The project involved the creation of two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment. The work included master cell bank creation, method implementation, pilot-scale evaluations, preparation for large-scale manufacturing, and regulatory documentation support. The two antibody fragments will be used in an upcoming, first-in-human, nuclear imaging microdosing study.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, AGC Biologics Completes Production of Cancer-Specific Antibody Fragments with VAR2 Pharmaceuticals
